New MGA White Paper Explores Lessons for the United States from Europe’s Biosimilar Experience
As the United States marks the tenth anniversary of the establishment of a biosimilars pathway, many experts express frustration that the US lags behind
Europe. A new white paper from Matrix Global Advisors carefully examines the US and European biosimilars markets and finds that the comparison between the markets is nuanced.
While Europe is often touted as the ideal market for biosimilars to flourish, the experience in reality differs from country to country. This paper delves
into the lessons the United States should adopt to speed the development of its market while also highlighting European market pitfalls to avoid.
For a PDF of the full report, click here.